Datafarm Announces the Release of Web-Based eCTD Viewer
Datafarm announces the release of a simple and cost effective Web-based eCTD viewer for companies of all sizes.
Philadelphia, 19 June 2006-Datafarm, the leading provider of electronic regulatory submission solutions, today announced the availability of eCTDViewer® Web Edition Version 3.0. This Web-based eCTD viewing solution includes support for all recent eCTD specifications and guidelines published by ICH, FDA, EMEA (including the most recent v1.2 specifications), Japan, Health Canada and Taiwanese agencies. This business tool offers zero desktop footprint and is designed meet the needs of companies of all sizes.
eCTDViewer Web Edition is built upon recognized technology standards such as HTML, XML, and JAVA. This combination of cross-platform technologies makes the application easy to deploy on both Windows and Linux servers, and allows it to support multiple application servers such as BEA WebLogic and Apache Tomcat. By using this standards-based approach, Datafarm has made it possible for any organization, regardless of size, to seamlessly incorporate eCTDViewer® Web Edition into their existing environment.
Datafarm's eCTD suite of applications includes eCTDBuilder®, used for submission compilation, and eCTDViewer® for submission review and paper dossier creation. This suite is currently used by over 40 companies in the US, EU, Canada and Japan who have successfully submitted over 800 submissions to the regulatory authorities.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
